Dazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial
TRS01 offers the potential to serve as an effective and safe treatment option in NIU that meets the urgent need for a drug that controls inflammation without the steroids' associated risk of IOP elevation.
Authors
- Kenneth Sall (ORCID: https://orcid.org/0000-0002-8868-4894)
- Michael Korenfeld (ORCID: https://orcid.org/0000-0003-1804-5525)
- Cadmus Rich
- Edmund Yik Kong Tsui (ORCID: https://orcid.org/0000-0001-7532-9191)
- Palestine Ag
- Dacey Ml
- Lana M. Rifkin
- Zohar Milman
- Ron Neumann
- David Chu (ORCID: https://orcid.org/0000-0002-8832-1815)
- I. Ben Ghezala
- David B. Abrams (ORCID: https://orcid.org/0000-0002-0868-4350)
- D. C. Scales
- Eric L. Crowell (ORCID: https://orcid.org/0000-0002-6986-5307)
- Emilee H. Fulcher
- Daphne Haim-Langford
- Lana M. Rifkin
- Doran Spencer
- Annal D. Meleth (ORCID: https://orcid.org/0000-0002-6650-9999)
- Christoph Deuter
- Stephan Thurau
- Marc D. de Smet
- Jennifer E. Thorne
- Edmund Tsui
- Alan G. Palestine
- David S. Chu
- A. Brézin
- Robert Finger
- C. Stephen Foster
- John Sheppard
- Rajiv Shah
- Sapna Gangaputra
- Khaled Tawansy
- Michel Weber
- Thomas Ness
- Frank McDonald
- Robert Wang
- Rainer Guthoff
Institutions
- Rutgers, The State University of New Jersey (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- New York Eye and Ear Infirmary (US)
- Johns Hopkins Medicine (US)
- Ophthalmic Consultants of Boston (US)
- Mapi Pharma (Israel) (IL)
- University of Colorado Denver (US)
Publication Details
- Journal
- American Journal of Ophthalmology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1016/j.ajo.2025.12.034
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00